Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Laurie Sewell-Muller

Nurse Practitioner, Psychiatric/Mental Health Omaha, NE Nurse Practitioner

NPI 1518685254 CMS profile 11357214

6910 Pacific St Ste 100, Omaha, NE 68106

Open in the dashboard

General payments

$4,607

275 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laurie Sewell-Muller of Omaha, NE is reported in the CMS Open Payments database as having received $4,607 across 275 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,131 134
2024 General $2,059 122
2023 General $417 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurie Sewell-Muller
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Laurie Sewell-Muller were reported at $2,131. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Laurie Sewell-Muller Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $0 $195 $66–$559 $149
2023 $417 $233 $82–$673 $160
2024 $2,059 $236 $84–$688 $164
2025 $2,131 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $587 44 payments
  2. ITI, Inc. $536 30 payments
  3. Axsome Therapeutics, Inc. $476 26 payments
  4. Alkermes, Inc. $459 24 payments
  5. Harmony Biosciences LLC $380 24 payments
  6. Vanda Pharmaceuticals Inc. $357 23 payments
  7. Lundbeck LLC $238 14 payments
  8. Teva Pharmaceuticals USA, Inc. $227 14 payments
  9. Otsuka America Pharmaceutical, Inc. $206 11 payments
  10. E.R. Squibb & Sons, L.L.C. $187 10 payments
  11. Other $955 55 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,584 273 payments
  2. Education $24 2 payments
Products named General payments · program years 2023–2025
  1. Auvelity $370 18 payments
  2. FANAPT $357 23 payments
  3. ARISTADA Cns $343 19 payments
  4. ARISTADA Cns $343 19 payments
  5. ARISTADA Cns $343 19 payments
  6. ARISTADA Cns $343 19 payments
  7. LYBALVI $301 21 payments
  8. CAPLYTA Psychiatry $297 16 payments
  9. QULIPTA $253 18 payments
  10. CAPLYTA Psychiatry $239 14 payments
  11. Other $3,644 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

458

Median for Nurse Practitioner: 389

Drug cost

$25,688

Median for Nurse Practitioner: $21,885

Branded share of claims

17.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 13 $18,365
Bupropion Xl Bupropion Hcl Brand 35 $1,709
Duloxetine Hcl Generic 23 $1,025
Quetiapine Fumarate Generic 57 $768
Aripiprazole Generic 20 $768
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 11 $447
Escitalopram Oxalate Generic 31 $309
Benztropine Mesylate Generic 22 $296
Mirtazapine Generic 20 $254
Trazodone Hcl Generic 31 $252

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $239
$239 — —
WAKIX
  • Harmony Biosciences LLC $202
$202 — —
VRAYLAR
  • AbbVie, Inc. $185
$185 13 —
REXULTI
  • Lundbeck LLC $79
  • Otsuka America Pharmaceutical, Inc. $75
$154 — —
Auvelity
  • Axsome Therapeutics, Inc. $145
$145 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record